Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 15 | 2026 | 2599 | 1.240 |
Why?
|
| Benchmarking | 2 | 2026 | 136 | 0.630 |
Why?
|
| Cyclin-Dependent Kinase 6 | 3 | 2026 | 50 | 0.510 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2026 | 66 | 0.510 |
Why?
|
| Language | 1 | 2026 | 216 | 0.410 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 510 | 0.410 |
Why?
|
| Educational Measurement | 1 | 2026 | 318 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2026 | 1314 | 0.370 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2026 | 613 | 0.370 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 351 | 0.330 |
Why?
|
| Ovarian Neoplasms | 3 | 2021 | 422 | 0.310 |
Why?
|
| Receptors, Estrogen | 4 | 2026 | 731 | 0.310 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1121 | 0.300 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 736 | 0.280 |
Why?
|
| Anthracyclines | 1 | 2026 | 43 | 0.240 |
Why?
|
| Osteoclasts | 1 | 2026 | 69 | 0.230 |
Why?
|
| Neurofibromin 1 | 1 | 2026 | 57 | 0.230 |
Why?
|
| Eligibility Determination | 1 | 2024 | 37 | 0.220 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2026 | 252 | 0.210 |
Why?
|
| Patient Selection | 2 | 2024 | 722 | 0.210 |
Why?
|
| Bone Neoplasms | 1 | 2026 | 471 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 155 | 0.160 |
Why?
|
| Prognosis | 5 | 2024 | 4861 | 0.160 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2020 | 104 | 0.150 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 708 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 85 | 0.150 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 47 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2026 | 2011 | 0.130 |
Why?
|
| Female | 17 | 2026 | 70354 | 0.120 |
Why?
|
| Receptors, Progesterone | 3 | 2026 | 679 | 0.120 |
Why?
|
| Aminopyridines | 2 | 2026 | 64 | 0.110 |
Why?
|
| Humans | 20 | 2026 | 130441 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1268 | 0.110 |
Why?
|
| Exosomes | 1 | 2014 | 61 | 0.100 |
Why?
|
| Benzimidazoles | 2 | 2026 | 155 | 0.100 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 284 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1157 | 0.100 |
Why?
|
| Naphthoquinones | 1 | 2012 | 10 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2026 | 3717 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 112 | 0.090 |
Why?
|
| Autophagy | 1 | 2014 | 422 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 615 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 589 | 0.070 |
Why?
|
| Genetic Counseling | 2 | 2021 | 237 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2026 | 1280 | 0.070 |
Why?
|
| Biomarkers, Tumor | 3 | 2023 | 1585 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 387 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 1 | 2026 | 19 | 0.060 |
Why?
|
| Taxoids | 1 | 2026 | 73 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2026 | 75 | 0.060 |
Why?
|
| Coculture Techniques | 1 | 2026 | 230 | 0.060 |
Why?
|
| Purines | 1 | 2026 | 115 | 0.060 |
Why?
|
| Middle Aged | 5 | 2026 | 28395 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2026 | 6424 | 0.050 |
Why?
|
| Pyridines | 1 | 2026 | 258 | 0.050 |
Why?
|
| Piperazines | 1 | 2026 | 269 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2026 | 427 | 0.050 |
Why?
|
| Aged | 4 | 2026 | 20888 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2023 | 29 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2023 | 50 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2021 | 1107 | 0.050 |
Why?
|
| Gene Expression | 2 | 2020 | 1486 | 0.050 |
Why?
|
| Everolimus | 1 | 2023 | 50 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2023 | 364 | 0.050 |
Why?
|
| Rural Population | 1 | 2024 | 272 | 0.050 |
Why?
|
| Diarrhea | 1 | 2023 | 316 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2026 | 1270 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2021 | 47 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 58 | 0.040 |
Why?
|
| Penetrance | 1 | 2020 | 108 | 0.040 |
Why?
|
| Mastectomy | 1 | 2019 | 74 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 3406 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 155 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 254 | 0.040 |
Why?
|
| Mutation | 2 | 2023 | 6098 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 464 | 0.030 |
Why?
|
| Adult | 3 | 2026 | 31121 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2020 | 346 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 901 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 2194 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 978 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 822 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1483 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 626 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 5153 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 899 | 0.030 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2014 | 12 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2014 | 33 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2014 | 22 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 81 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 426 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 329 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 159 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1388 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 192 | 0.030 |
Why?
|
| Mice | 2 | 2026 | 18229 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 192 | 0.020 |
Why?
|
| Biomarkers | 1 | 2023 | 3386 | 0.020 |
Why?
|
| Apoptosis | 1 | 2020 | 1828 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 186 | 0.020 |
Why?
|
| Time Factors | 1 | 2023 | 6201 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2012 | 25 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 23 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2014 | 259 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 101 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2012 | 56 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 100 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 414 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 228 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 585 | 0.020 |
Why?
|
| Cisplatin | 1 | 2012 | 274 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 679 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 330 | 0.020 |
Why?
|
| Glucose | 1 | 2014 | 852 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 817 | 0.020 |
Why?
|
| Animals | 2 | 2026 | 33857 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 1000 | 0.020 |
Why?
|
| United States | 1 | 2024 | 11874 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 521 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 722 | 0.020 |
Why?
|
| Calcium | 1 | 2012 | 1022 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1592 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 2464 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 1799 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 17514 | 0.010 |
Why?
|
| Male | 1 | 2021 | 64473 | 0.010 |
Why?
|